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Abstract
Background: End-stage renal disease (ESRD) is associated with uremia and increased systemic inflammation.
Alteration of the intestinal microbiota may facilitate translocation of endotoxins into the systemic circulation leading
to inflammation. We hypothesized that children with ESRD have an altered intestinal microbiota and increased
serum levels of bacterially derived uremic toxins.
Methods: Four groups of subjects were recruited: peritoneal dialysis (PD), hemodialysis (HD), post-kidney transplant
and healthy controls. Stool bacterial composition was assessed by pyrosequencing analysis of 16S rRNA genes.
Serum levels of C-reactive protein (CRP), D-lactate, p-cresyl sulfate and indoxyl sulfate were measured.
Results: Compared to controls, the relative abundance of Firmicutes (P = 0.0228) and Actinobacteria (P = 0.0040)
was decreased in PD patients. The relative abundance of Bacteroidetes was increased in HD patients (P = 0.0462).
Compared to HD patients the relative abundance of Proteobacteria (P = 0.0233) was increased in PD patients. At the
family level, Enterobacteriaceae was significantly increased in PD patients (P = 0.0020) compared to controls; whereas,
Bifidobacteria showed a significant decrease in PD and transplant patients (P = 0.0020) compared to control. Alpha
diversity was decreased in PD patients and kidney transplant using both phylogenetic and non-phylogenetic diversity
measures (P = 0.0031 and 0.0003, respectively), while beta diversity showed significant separation (R statistic = 0.2656,
P = 0.010) between PD patients and controls. ESRD patients had increased serum levels of p-cresyl sulfate and indoxyl
sulfate (P < 0.0001 and P < 0.0001, respectively). The data suggests that no significant correlation exists between the
alpha diversity of the intestinal microbiota and CRP, D-lactate, or uremic toxins. Oral iron supplementation results in
expansion of the phylum Proteobacteria.
Conclusions: Children with ESRD have altered intestinal microbiota and increased bacterially derived serum uremic toxins.
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Background
The intestinal microbiota is the largest symbiotic ecosys-
tem in the human body. The gastrointestinal tract (GI)
is colonized by trillions of bacteria. In healthy adults,
almost 90 % of the identified fecal microbiota can be
classified into two predominant phyla, Bacteroidetes and
Firmicutes. The intestinal microbiota is highly variable
during the first years of life, reaching an adult-like
composition by 3 years and remains relatively stable [1].
Changes in the composition of the intestinal microbiota
have been implicated in the pathogenesis of multiple dis-
eases in children and adults [2, 3].
Patients with end stage renal disease (ESRD) have an
increase in cardiovascular disease which cannot be ex-
plained by traditional risk factors alone. There is evi-
dence that uremia in ESRD disrupts the intestinal
barrier structure, specifically the tight junctions, and
impairs intestinal motility [4–7]. These changes may
facilitate the translocation of endotoxins and bacterial
metabolites into the systemic circulation leading to
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systemic micro-inflammation [8, 9] and increased car-
diovascular disease [10–13]. Blood markers such as
D-lactate and endotoxin lipopolysaccharide (LPS), which
are metabolic products or components of intestinal bac-
teria, have been used as indicators of intestinal perme-
ability [14]. Evaluation of intestinal wall integrity is a
challenge in patients with reduced renal residual func-
tion, because it depends on renal excretion of the orally
ingested molecules.
Several factors may influence the intestinal microbiota
of ESRD patients. The dietary restriction of potassium
may inadvertently cause a reduction in the insoluble
fiber intake of these patients [15]. This may ultimately
lead to a reduction of normal gut flora which ferment
fiber to produce short chain fatty acids (SCFA) which
act as a key energy source for colorectal tissues and sym-
biotic microbes [16]. Further, studies in adults demon-
strate that uremia results in a shift in the intestinal
microbiota, favoring bacteria capable of surviving in the
new biochemical environment [17]. The metabolites
produced by this altered colonic flora result in the
accumulation of uremic toxins such as indoxyl sulfate
and p-cresyl sulfate [18]. Eighteen bacterial families with
4-hydroxyphenylacetate decarboxylase (4-Hpd) and tryp-
tophanase are responsible for the formation of p-cresyl
sulfate and indoxyl sulfate, respectively [15, 19]. In
addition, recent studies have demonstrated that uremia
may also increase ammonia production leading to in-
creased luminal pH and resulting in mucosal damage
and irritation [15]. These uremic toxins, which are nor-
mally excreted by the kidney via tubular secretion, are
poorly cleared by dialysis [20–22]. Several investigators
have reported an association between elevated levels of
p-cresyl sulfate and indoxyl sulfate with an increased risk
of cardiovascular disease and other adverse effects in
adults with ESRD [23, 24].
The impact of uremia on the intestinal microbiota of
pediatric patients with ESRD is unknown. It is also un-
clear if renal transplantation has an effect on the com-
position of the intestinal microbiota, uremic toxin
production, or systemic inflammation. Hence, our pri-
mary aim was to study the intestinal microbiota of
pediatric patients with ESRD and after kidney trans-
plantation. Our secondary aim was to evaluate the cor-
relation between altered intestinal microbiota, D-lactate,
C-reactive protein (CRP), and the presence of bacterially




This is a cross sectional study comparing four groups of
pediatric patients (2 to 18 years of age). Thirty-nine pa-
tients were enrolled: eight patients on hemodialysis
(HD), eight patients on peritoneal dialysis (PD), ten pa-
tients with a kidney transplant and 13 age-matched
healthy controls. Participants were recruited from partici-
pating centers of the Midwest Pediatric Nephrology
Consortium (Children’s Hospital of New Orleans, Women
and Children’s Hospital of Buffalo, and Children’s
Healthcare of Atlanta) from June 2014 to March 2015.
Patient demographic and clinical characteristics are shown
in Table 1.
We excluded patients with history of diabetes, pan-
creatitis, cirrhosis, inflammatory bowel disease, diarrhea,
severe constipation, or use of antibiotics within 1 month.
Additional exclusion criteria included kidney transplant
recipients with an estimated glomerular filtration rate
(eGFR) of less than 60 ml/min/1.73 m2, acute rejection
or transplant within the last 6 months. Written informed
consent was obtained from a legal guardian or the
patient if 18 years old, and assent was obtained in pa-
tients older than 7 years. The study was approved by the
Louisiana State University Health Sciences Center
Institutional Review Board (IRB # 8554).
Stool sample collection
One stool sample (1–2 g) was collected from each sub-
ject. We provided instructions describing how to collect
stool specimens, place them in nucleic acid preservative,
and deliver them to our Research Center within 24 to
48 h after collection. Stool specimens were collected in
Assay Assure (Sierra Molecular, Incline Village, NV),
which does not require refrigeration. DNA was isolated
from the stool samples within 48 h of receipt and stored
at −20 °C.
16S rRNA sequencing
Stool DNA was isolated using a QIAamp Fast DNA
Stool Mini kit (Qiagen, Germantown, Maryland) modi-
fied to include a sonication step. Sequencing and bio-
informatics were performed by the Louisiana State
University Microbial Genomics Resource Center. The
16S ribosomal DNA hypervariable regions V3 and V4
were PCR-amplified using primers V3F CCTACGGGAG
GCAGCAG and V4R GACTACHVGGGTWTCTAAT
with Illumina adaptors and molecular barcodes as
described in Kozich et al. [25] to produce 430 base pair
(bp) amplicons. Samples were sequenced on an Illumina
MiSeq (Illumina, San Diego, CA) using a V3 sequencing
kit (300 bp paired end reads).
The forward and reverse-read files were processed
through the UPARSE pipeline (drive5, Tiburon, California)
[26]. Forward and reverse reads were merged with a
merge truncation quality of 2 as recommended by Edgar
for Illumina data. Merged amplicons were filtered using a
filter truncation quality of ten and resulting amplicons
were truncated to a length of 400 bp. Singleton reads
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(reads that appeared only once across all samples) were
removed from the resulting filtered reads and remaining
reads were clustered into operational taxonomic units
(OTUs) at 97 % similarity. Chimeric OTUs were removed
as identified by UCHIME drive5 run against a gold stand-
ard reference database (ChimeraSlayer reference database)
of nonchimeric sequences.
Finally, the original filtered reads (before dereplication)
were mapped to the OTUs using USEARCH drive5 at
97 % identity. QIIME 1.8 (open source, www.qiime.org)
was used to pick and align a representative set. The
Ribosomal Database Project classifier was used to assign
a taxonomic classification to each read in the represen-
tative set and a phylogenetic tree was constructed from
the representative sequences. Among samples, the mini-
mum read count after filtering was 7371 reads and the
median read count after filtering was 13,226 reads. The
OTUs were assigned to the lowest possible taxonomic
level. Bacterial alpha diversity among groups was calcu-
lated using phylogenetic whole tree and Chao 1 within
QIIME. The bacterial beta diversity was assessed using
the principal coordinates analysis (PCoA) of weighted
UniFrac distances within QIIME.
Blood sample collection
Blood specimen was drawn as part of routine labora-
tory sampling. For HD patients, blood was taken im-
mediately prior to the midweek dialysis session. Using
a 5-ml serum separator tube (SST) with polymer gel
and clot activator, 5 ml of venous blood was col-
lected. Following standard separation procedure,
serum was isolated and stored at −80 °C. Renal func-
tion was assessed by measuring blood urea nitrogen
(BUN) and creatinine then calculating the estimated
glomerular filtration rate (eGFR) using the modified
Schwartz formula [27] (Table 1).
Bacterially derived uremic toxins
Serum p-cresyl sulfate and indoxyl sulfate were mea-
sured by high performance liquid chromatography
(HPLC) as described by de Loor et al. [28]. Briefly, two
aliquots of 200 μL of serum were added 20 μL of
0.50 mM 1-naphthalenesulfonic acid (internal standard)
and vortex-mixed with 250 μL of 0.24 M sodium octano-
ate (binding competitor). After incubation at room
temperature for 5 min, 2 mL of cold acetone was added
to precipitate proteins. Following vortex-mixing and
centrifuging at 4°C, 1860×g for 20 min, the supernatant
was transferred to 12 × 100 mm, GL 14 glass test tubes
and 2 mL of dichloromethane was then added. After
vortex-mixing and centrifuging at 4°C, 1860×g for 10 min,
200 μL of the upper layer was transferred to glass auto-
sampler vials, followed by addition of 20 μL 1 M HCl.
15 μL of this final solution was used for HPLC analysis.
A Shimadzu (Columbia, MD) Prominence LC-20AT
HPLC system with UV/Fluorescence detector and auto
sampler was used for determination of p-cresyl sulfate
and indoxyl sulfate. The analytes were resolved by using
a reverse phase Sunfire C18 column (150 × 3.0 mm;
3.5 μm particle size; Waters) with a Sunfire C18 guard
column (20 × 3.0 mm; 3.5 μm particle size; Waters) at a
flow rate of 0.5 ml/min. Mobile phase A was 0.2 % tri-
fluoroacetic acid in Milli-Q water and mobile phase B
was 0.2 % trifluoroacetic acid in acetonitrile. The analyt-
ical method consisted of a run with gradient elution
starting at 8 % phase B for 5 min, followed by a linear
increase to 18 % in 15 min, a linear change to 100 % in
5 min, a hold for 3 min and a final linear change back to
8 % phase B in 2 min, a return to the initial condition
for 10 min before next injection. Indoxyl sulfate eluted
at 13.8 min, p-cresyl sulfate at 20.4 min and internal
standard at 23.7 min. Column temperature was 25 °C,
and autosampler tray temperature was 6 °C. We quanti-
fied the analytes by using the analyte to standard peak
Table 1 Cohort characteristics
Control ESRD-HD ESRD-PD Transplant
N (blood/stool) 13/11 8/7 8/7 10/9
Sex (male:female) 6:7 5:3 4:4 10:0
Age (years) 9.5 (3–16) 13.6 (8–17) 11.9 (3-17) 13.2 (2–18)
BMI (kg/m2) 23.15 (14.9–53) 22.1 (16.6–28) 17.8 (14.8–23.4) 18.8 (15.3–23.8)
Time on dialysis (months) N/A 23.3 (2–77) 21.5 (3–49) N/A
Kt/v N/A 1.8 (1.22–2.7) 2.2 (1.89–2.5) N/A
Time from transplant (month) N/A N/A N/A 43.1 (10–110)
BUN (mg/dl) 13.54 (8–19) 51.00 (33–125) 41.38 (14–65) 17.78 (9–26)
Serum creatinine (mg/dl) 0.37 (0.10–0.70) 8.58 (0.90–18.10) 11.70 (7.40–19.00) 0.99 (0.50–1.60)
eGFR 118 (85-139) <15 <15 78 (61–108)
ESRD-HD end-stage renal disease on hemodialysis, ESRD-PD end-stage renal disease on peritoneal dialysis, N/A not available, N number of samples, Kt/v dialysis
dose, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate
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area ratios on a Shimadzu RF-20A xs fluorescence de-
tector. Detector settings were λex 260 nm/λem 288 nm
for p-cresyl sulfate and λex 280 nm/λem 390 nm for in-
doxyl sulfate and internal standard.
Calibration curves
Calibrators containing indoxyl sulfate and p-cresyl sul-
fate at a final concentration between 1.5 and 400.0 μM
were prepared in phosphate buffered saline. Two calibra-
tion curves were constructed with a linear response ran-
ging from 1.5 to 50.0 μM (low) and 1.5 to 400.0 μM
(high). Regression equations were reported as mean
(standard deviation (SD)) from three independent curves
for indoxyl sulfate were as follows:
y = 0.06 × (0.00072) + 0.3 (0.11) (high curve)
y = 0.07(0.0018) × ‐ 0.01 (0.0042) (low curve)
The regression equations for p-cresyl sulfate were as
follows:
y = 0.0083(0.00057) × + 0.02(0.0088) (high curve)
y = 0.0092(0.00036) × + 0.003(0.00086) (low curve)
Overall coefficient of determination (R2) was 0.999
Inflammatory marker and D-lactate measurement
Serum CRP was determined using the human C-Reactive
Protein ELISA kit (Sigma-Aldrich, St. Louis, MO) accord-
ing to manufacturer’s instruction. Serum D-lactate level
was determined using the D-lactate colorimetric assay kit
(Sigma-Aldrich, St. Louis, MO) according to the manufac-
turer’s instruction.
Statistical analysis
Alpha diversity was measured using phylogenetic diver-
sity whole tree and Chao1 within QIIME, using the aver-
age of ten iterations in which 6600 sequences were
randomly sampled from each specimen. Diversity was
compared between PD, HD, post-transplant, and control
groups. Statistical differences in bacterial community
composition between groups of specimens were assessed
using analysis of similarity (ANOSIM) and principal co-
ordinates analysis (PCoA) of weighted UniFrac distances
within QIIME [29]. Comparison of multiple groups was
performed by the nonparametric Kruskal-Wallis test
followed by Dunn’s multiple comparisons test within
GraphPad PRISM 6 (Graph Pad Software Inc., San Diego,
CA). Correlation analysis was assessed by Spearman non-
parametric correlation within PRISM. Box and whisker
plots illustrate median (line within the box) and minimum
and maximum values (whiskers).
Results
Relative abundance of bacterial taxa
There were notable differences in the relative abun-
dances of intestinal bacteria at the phylum level between
patient groups (Fig. 1). The relative abundance of bac-
teria within the phylum Firmicutes was significantly
lower in PD patients (P = 0.0228) compared to healthy
controls (Fig. 2a). Whereas the relative abundance of the
phylum Bacteroidetes was significantly increased in HD
patients (P = 0.0462) compared to healthy controls (Fig. 2b).
There were also significant differences in the relative abun-
dances of phyla across dialysis modalities. The phylum
Proteobacteria was significantly increased in patients on PD
(P = 0.0233) compared to patients on HD (Fig. 2c).
Actinobacteria was significantly decreased in PD patients
(Fig. 2d) compared to controls (P = 0.0040).
Bacterial diversity
Alpha diversity was significantly decreased in patients
on PD and in patients with kidney transplants, when
compared to patients on HD and controls, using both
phylogenetic (Fig. 3a) and non-phylogenetic (Fig. 3b)
diversity measures (P = 0.0031 and 0.0003, respectively).
Bacterial community composition
PCoA analysis of weighted UniFrac distances showed
significant separation between microbial communities
(Fig. 4) of patients with ESRD on PD compared to
healthy control group, (R statistic = 0.2656, P = 0.010,
ANOSIM).
Indole and P-cresol producing taxa
Enterobacteriaceae was significantly increased in patients
with ESRD who were on PD (Fig. 5a) compared to con-
trols (P = 0.0020). We found no significant difference in
Clostridiaceae across any patient groups (Fig. 5b). Bifido-
bacteriaceae was significantly decreased (P = 0.0020) in
PD and with kidney transplant patients when compared to
controls (Fig. 5c). There was no significant difference ob-
served in the Lactobacillaceae family between any of the
patient groups (Fig. 5d).
Serum p-cresyl sulfate and indoxyl sulfate levels
Patients with ESRD, either on HD or PD, had signifi-
cantly increased levels of the uremic toxins p-cresyl
sulfate (P < 0.0001) and indoxyl sulfate (P < 0.0001) com-
pared to control and transplant patients (Fig. 6a, b,
respectively). There was no significant difference be-
tween HD and PD patients.
Serum CRP and D-lactate
There were no significant differences observed for
serum CRP or serum d-lactate level among the study
groups (Fig. 7a, b).
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Correlation of species richness and serum biomarkers
There was no significant correlation between alpha di-
versity measures (PD whole tree) and serum CRP, D-lac-
tate, or uremic toxins (Fig. 8).
Discussion
To our knowledge, this study is the first to assess the
composition of the intestinal microbiota of pediatric pa-
tients with ESRD or kidney transplants. Recent studies
have revealed the fundamental role of the intestinal
microbiota in the maintenance of normal human physi-
ology and homeostasis. This complex ecosystem within
the gut is highly susceptible to disturbances that can
alter the composition of the intestinal microbiota. We
demonstrate that children and adolescents with ESRD
and kidney transplant exhibit an altered intestinal micro-
biota. PD patients, as well as those with a kidney trans-
plant, exhibited significantly decreased bacterial diversity
(alpha diversity) compared to control. In addition, the
composition of bacterial communities (beta diversity)
within our PD patients was significantly different when
compared to the healthy control group. Serum levels of
bacterially derived uremic toxins, p-cresyl and indoxyl
sulfate, were significantly increased in ESRD patients.
The GI tract hosts a broad range of bacterial species.
It is estimated that between 500 and 1000 species are
Fig. 1 Taxonomic composition of the intestinal microbiota. Percent abundance of bacterial phyla
Fig. 2 Relative abundance of the four dominant phyla of the intestinal microbiota. a Patients on PD showed significantly reduced abundance in
Firmicutes (P = 0.0228) when compared to healthy control. b Bacteroidetes was significantly increased in HD patients (P = 0.0462) when compared to
control. c Proteobacteria was significantly increased in PD patients (P = 0.0233) when compared to HD patients. d The abundance of Actinobacteria
was significantly decreased in PD patients (P = 0.004) when compared to control. Kruskal-Wallis test followed by Dunn’s multiple comparisons test.
N = 6–11 in individual groups. Box and whisker plots illustrate median (line within the box) and minimum and maximum values (whiskers)
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resident at any given time, but four divisions predomin-
ate: Firmicutes, Bacteroidetes, Proteobacteria, and
Actinobacteria. Firmicutes constitute ~64 % of the
microbiota, whereas Bacteroidetes account for ~23 % of
the normal microbiota [30]. In chronic conditions such
as type 2 diabetes mellitus and inflammatory bowel dis-
ease, patients develop dysbiosis, defined as an abnormal
ratio of beneficiary and aggressive bacterial species [31].
We found that patients with ESRD on PD had a de-
creased relative abundance of the phylum Firmicutes
(Fig. 2a), while HD patients exhibited an increase to the
phylum Bacteroidetes (Fig. 2b) when compared to
healthy control patients. The same pattern of gut dysbio-
sis was reported in patients with type-2 diabetes [32].
In addition to uremia, several possible mechanisms
may account for the observed changes to the intestinal
microbiota. Proteobacteria, also known as the iron oxi-
dizing bacteria, are typically present in small amounts in
the healthy adult intestinal microbiota [33]. However,
our results demonstrate that Proteobacteria were in-
creased in patients on PD (Fig. 2c) when compared to
HD patients. This may be due to the oral iron supple-
mentation received by PD patients. Although both ESRD
groups receive iron supplementation, the route of deliv-
ery differs for the two dialysis modalities. Whereas HD
patients receive iron supplementation directly into the
bloodstream, PD patients ingest iron supplements. The
interaction of orally ingested iron with gut microbes able
to metabolize this mineral may account for the increased
Proteobacteria levels. Further, Enterobacteriaceae, a fam-
ily belonging to the phylum Proteobacteria, exhibited a
significant increase in abundance among PD patients
compared to control patients (Fig. 5a). The Enterobacte-
riaceae are known to ferment glucose and account for
up to 12 % of all peritonitis episodes in patients with
ESRD treated with PD [34]. We speculate that the ob-
served increase in Enterobacteriaceae in PD patients may
be due to intestinal absorption of glucose from the dialys-
ate. This increase in Enterobacteriaceae may contribute to
peritonitis infections observed in PD patients. Future
studies are needed to better evaluate these findings.
Patients on PD had a significantly decreased abun-
dance of the phylum Actinobacteria (Fig. 2d). Con-
versely, Wu et al. demonstrated that increased
Actinobacteria was associated with a healthy gut micro-
biome in children [35]. Bifidobacterium, a family belong-
ing to the phylum Actinobacteria, also exhibited a
decreased abundance in PD and kidney transplant pa-
tients (Fig. 5c). These organisms might be responsible
for a variety of beneficial health effects, including the
regulation of intestinal microbial homeostasis and the
inhibition of harmful bacteria that colonize or infect the
gut mucosa [36]. Bifidobacterium improve the gut mu-
cosal barrier and lower levels of lipopolysaccharide in
Fig. 3 Microbial alpha diversity. Box plots were generated to compare the bacterial richness within groups. Patients with ESRD on PD as well as
kidney transplant patients had significantly decreased alpha diversity as demonstrated by different metrics of alpha diversity: (a) phylogenetic
diversity whole tree (P = 0.0031) and (b) chao-1 richness estimation (P = 0.003). Kruskal-Wallis test followed by Dunn’s multiple comparisons test.
N = 7–11 in individual groups. Box and whisker plots illustrate median (line within the box) and minimum and maximum values (whiskers)
Fig. 4 Microbial beta diversity. Principal coordinate analysis (PCoA) of
PD patients compared to control. Weighted UniFrac distance showed
significant separation between microbial communities in patients with
ESRD on PD (blue dots) and the healthy control patients (red dots)
(R statistic = 0.2656, P = 0.010)
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the intestine [37]. Alterations in the integrity of the in-
testinal mucosa facilitate the translocation of bacterially
derived toxins.
Loss of bacterial diversity has been shown to play a
role in the severity of clinical features of infants with
necrotizing enterocolitis (NEC) [38] and adult patients
with chronic obstructive lung disease (COPD) [39]. This
suggests an association between loss of bacterial diver-
sity and disease severity. There was a significant de-
crease in the number of species (alpha diversity) in our
patients on PD and with a kidney transplant, when com-
pared to patients on HD and controls using both
phylogenetic (Fig. 3a) and non-phylogenetic diversity
measures (Fig. 3b). In future studies, we will address the
question of whether the observed alpha diversity in chil-
dren with ESRD affects the severity or rate of complica-
tions. Results of the beta diversity analysis, illustrated by
PCoA plot (Fig. 4), showed a significant difference in
UniFrac distances between ESRD on PD and control mi-
crobial communities. Our results represent an initial
insight into the intestinal microbiome patterns in ESRD,
which would need to be confirmed in larger cohorts.
Of note, transplant patients exhibited decreased spe-
cies diversity and decreased abundance of Bifidobacteria
Fig. 5 Relative abundance of intestinal microbiota at the family level. a Enterobacteriaceae was significantly increased in patients on peritoneal
dialysis (P = 0.0020). b Clostridiaceae showed no significant difference among the groups (P = 0.8378). c The abundance of Bifidobacteriaceae was
significantly decreased in PD and transplant patients (P = 0.0020). d There were no significant differences in Lactobacillaceae among the groups
(P = 0.8765). Kruskal-Wallis test followed by Dunn’s multiple comparisons test. N = 6–11 in individual groups. Box and whisker plots illustrate median
(line within the box) and minimum and maximum values (whiskers)
Fig. 6 Serum levels of bacterially produced uremic toxins. ESRD patients showed significantly increased levels of (a) p-cresyl sulfate P < 0.0001
(Kruskal-Wallis test followed by Dunn’s multiple comparisons test.) and (b) indoxyl sulfate P < 0.0001 (Kruskal-Wallis test followed by Dunn’s
multiple comparisons test.). N = 7–12 in individual groups. Box and whisker plots illustrate median (line within the box) and minimum and maximum
values (whiskers)
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(Fig. 3a, b, and Fig. 5c, respectively). Several studies have
reported shifts in gut microbiota, including loss of dom-
inant phyla and decreased species diversity, following
organ transplantation [40–42]. These alterations may be
the result of antibiotic treatment, immunosuppression
therapy or a combination of the two. Further studies will
be needed to elucidate the mechanism by which these
alterations are occurring.
Serum concentrations of p-cresyl sulfate and indoxyl
sulfate have been associated with progression of chronic
kidney disease [21, 23], increased cardiovascular disease
[10–13] and overall mortality in adult patients with
chronic kidney disease. Previous studies found that the
high protein binding affinity of both bacterially derived
uremic toxins markedly limits their removal by dialysis,
even with the use of high-flux membranes [43]. Serum
levels of p-cresyl sulfate and indoxyl sulfate seem to cor-
relate with loss of residual renal function [44]. Recent
animal studies, demonstrated that p-cresyl sulfate and
indoxyl sulfate are excreted by renal tubular secretion
via organic anion transporters [45]. Similar to adult
studies, we found significantly increased levels of p-cre-
syl sulfate and indoxyl sulfate in our pediatric patients
with ESRD. Kidney transplantation results in
normalization of serum indoxyl sulfate and p-cresyl sul-
fate, despite decreased bacterial diversity. These findings
suggest that renal clearance via tubular secretion is of
paramount importance for maintaining normal serum
Fig. 7 Serum level of CRP and D-lactate. ESRD patients showed no significant differences for (a) serum CRP P= 0.0590 or (b) serum D-lactate P= 0.5669
(Kruskal-Wallis test followed by Dunn’s multiple comparisons test.). N= 8–12 in individual groups. Box and whisker plots illustrate median (line within the box)
and minimum and maximum values (whiskers)
Fig. 8 Correlations between alpha diversity and serum biomarkers. Alpha diversity showed no significant correlation between (a) serum CRP
(r = −0.2110, P = 0.23), (b) serum D-lactate (r = 0.12, P = 0.50), (c) indoxyl sulfate (r = −0.12, P = 0.07), or (d) p-cresyl sulfate (r = −0.03, P = 0.89). Spearman
nonparametric correlation
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levels of both toxins. Accumulation of these uremic
toxins is considered one of the possible causes of
chronic inflammation in patients with ESRD.
Chronic inflammation is a well-established independ-
ent risk factor for cardiovascular disease. Patients with
ESRD have a high prevalence of micro-inflammation
[46–49]. In recent years, several studies have tried to
elucidate the etiology for this inflammatory state. The
relative roles of residual renal function, dialysis modality,
bacterial translocation, intestinal microbiota and the ac-
cumulation of endotoxins such as p-cresyl sulfate and
indoxyl sulfate in causing the inflammatory milieu of
CKD remains unclear. In our study, we assessed inflam-
mation by measuring serum CRP, but did not observe a
statistical difference between our groups of patients.
There was a trend toward higher serum CRP levels in
the patients with ESRD; however, the lack of statistical
significance may have been due to the high variation and
small sample sizes. Furthermore, we discovered that sev-
eral of our control patients were overweight or obese,
which is a confounding factor for inflammatory markers.
Visser et al. demonstrated that higher BMI was associ-
ated with increased CRP levels [50].
Evidence suggests that uremia may impair the intes-
tinal barrier function of ESRD patients [4–7]. This “leaky
gut” may allow the passage of endotoxins and bacterial
metabolites into the systemic circulation contributing to
systemic microinflammation [8, 9]. For this study, serum
D-lactate was used as an indirect marker of intestinal
permeability. There were no significant differences ob-
served between the groups. Although a previous study
reports elevated plasma D-lactate levels in ESRD pa-
tients, this observation was only seen in conjunction
with the presence of bacterial DNA in blood samples
[9]. Our study of serum D-lactate level does not include
simultaneous analysis of bacterial DNA in blood sam-
ples. This suggests that D-lactate alone may not inde-
pendently indicate the level of intestinal permeability in
ESRD patients.
The level of species richness, as measured by PD
whole tree, did not show a significant correlation with
any of the serum biomarkers used in this study. As
stated above, several factors may contribute to the lack
of correlation and statistically significant differences
among these groups of study. Although some studies
have demonstrated the correlation between specific in-
testinal microbes and biomarkers, to our knowledge this
is the first study to attempt to link the overall intestinal
species diversity with serum biomarkers in a pediatric
population. Further studies of larger cohort populations
will be needed to validate the results of this study.
Recent studies suggest that uremic by-products
induce toxicity by increasing the production of react-
ive oxygen species (ROS) through NADPH oxidase
(membrane-bound enzyme complex that generate
superoxide). ROS production generates the mitogen-
activated protein kinase (MAPK)/NF-kB (nuclear fac-
tor kB) pathway which leads to the production of
pro-inflammatory cytokines, chemokines and adhesion
molecules [51, 52]. Measurement of ROS in pediatric
ESRD patients is a potential avenue of investigation.
There are limitations in our study. Our sample size
was small, and this limited our statistical power. We
were unable to control for potential confounding vari-
ables such as dietary restrictions or BMI.
Conclusions
We have demonstrated that pediatric patients with
ESRD and kidney transplant have an altered intestinal
microbiota. The intestinal microbiota of ESRD patients
differs with dialysis modality.
Patients with ESRD have elevated levels of p-cresyl
sulfate and indoxyl sulfate.
Renal transplantation results in the normalization of
bacterially derived uremic toxins p-cresyl sulfate and in-
doxyl sulfate; however, renal transplantation does not
correct the decreased bacterial diversity.
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